These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16320411)

  • 21. Utility of Naltrexone Treatment for Chronic Inflammatory Dermatologic Conditions: A Systematic Review.
    Ekelem C; Juhasz M; Khera P; Mesinkovska NA
    JAMA Dermatol; 2019 Feb; 155(2):229-236. PubMed ID: 30484835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis.
    Bergasa NV; Schmitt JM; Talbot TL; Alling DW; Swain MG; Turner ML; Jenkins JB; Jones EA
    Hepatology; 1998 Mar; 27(3):679-84. PubMed ID: 9500694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vivitrex (Alkermes/Cephalon).
    Heading CE
    Curr Opin Investig Drugs; 2006 Jan; 7(1):81-8. PubMed ID: 16425675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of oral naltrexone on pruritus in cholestatic patients.
    Mansour-Ghanaei F; Taheri A; Froutan H; Ghofrani H; Nasiri-Toosi M; Bagherzadeh AH; Farahvash MJ; Mirmomen S; Ebrahimi-Dariani N; Farhangi E; Pourrasouli Z
    World J Gastroenterol; 2006 Feb; 12(7):1125-8. PubMed ID: 16534857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of naltrexone in the management of severe generalized pruritus in biliary atresia: report of a case.
    Chang Y; Golkar L
    Pediatr Dermatol; 2008; 25(3):403-4. PubMed ID: 18577062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex.
    Chindalore VL; Craven RA; Yu KP; Butera PG; Burns LH; Friedmann N
    J Pain; 2005 Jun; 6(6):392-9. PubMed ID: 15943961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-dose naltrexone for treatment of duodenal Crohn's disease in a pediatric patient.
    Shannon A; Alkhouri N; Mayacy S; Kaplan B; Mahajan L
    Inflamm Bowel Dis; 2010 Sep; 16(9):1457. PubMed ID: 20014017
    [No Abstract]   [Full Text] [Related]  

  • 28. Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects.
    McCaul ME; Wand GS; Eissenberg T; Rohde CA; Cheskin LJ
    Neuropsychopharmacology; 2000 May; 22(5):480-92. PubMed ID: 10731623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained-release naltrexone for alcoholism treatment: a preliminary study.
    Kranzler HR; Modesto-Lowe V; Nuwayser ES
    Alcohol Clin Exp Res; 1998 Aug; 22(5):1074-9. PubMed ID: 9726277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Research on low dosage naltrexone].
    Holmøy T
    Tidsskr Nor Laegeforen; 2011 Jul; 131(13-14):1277-8. PubMed ID: 21725378
    [No Abstract]   [Full Text] [Related]  

  • 31. The lowdown on low-dose naltrexone.
    Shabeeb N
    Cutis; 2020 Jan; 105(1):E17-E18. PubMed ID: 32074159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concerns about injectable naltrexone for opioid dependence.
    Wolfe D; Carrieri MP; Dasgupta N; Wodak A; Newman R; Bruce RD
    Lancet; 2011 Apr; 377(9776):1468-70. PubMed ID: 21529930
    [No Abstract]   [Full Text] [Related]  

  • 33. Formulation and stability of naltrexone oral liquid for rapid withdrawal from methadone.
    Fawcett JP; Morgan NC; Woods DJ
    Ann Pharmacother; 1997 Nov; 31(11):1291-5. PubMed ID: 9391680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A possible new treatment approach to obsessive-compulsive disorder.
    Warneke L
    Can J Psychiatry; 1997 Aug; 42(6):667-8. PubMed ID: 9288436
    [No Abstract]   [Full Text] [Related]  

  • 35. Long-acting depot formulations of naltrexone for heroin dependence: a review.
    Krupitsky EM; Blokhina EA
    Curr Opin Psychiatry; 2010 May; 23(3):210-4. PubMed ID: 20224403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients.
    Setnik B; Roland CL; Goli V; Sommerville K; Webster L
    J Opioid Manag; 2013; 9(2):139-50. PubMed ID: 23709323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Naltrexone Therapy for Hailey-Hailey Disease: Confirming My Addiction to Evidence-Based Medicine.
    Heymann WR
    Skinmed; 2019; 17(1):44-45. PubMed ID: 30888948
    [No Abstract]   [Full Text] [Related]  

  • 38. Low-Dose Naltrexone as First Option for Fibromyalgia Patients: A Case Series.
    de Carvalho JF
    Isr Med Assoc J; 2024 Aug; 26(7):441-442. PubMed ID: 39082454
    [No Abstract]   [Full Text] [Related]  

  • 39. [Low dosage naltrexone].
    Raknes G; Giverhaug T
    Tidsskr Nor Laegeforen; 2011 Aug; 131(15):1415-6. PubMed ID: 21844938
    [No Abstract]   [Full Text] [Related]  

  • 40. Plasma naltrexone during opioid detoxification.
    McDonald T; Berkowitz R; Hoffman WE
    J Addict Dis; 2000; 19(4):59-64. PubMed ID: 11110065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.